Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Physostigmine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE known ✓ | P22303 | 14/20 | 1.00 |
| ▸ | BCHE | P06276 | 11/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 7/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 2/20 | 1.00 |
| ▸ | HIF1A | Q16665 | 2/20 | 1.00 |
| ▸ | MEN1 | O00255 | 1/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 1/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 1/20 | 1.00 |
| ▸ | LMNA | P02545 | 1/20 | 1.00 |
| ▸ | PTGS1 | P23219 | 1/20 | 1.00 |
| ▸ | OPRM1 | P35372 | 1/20 | 1.00 |
| ▸ | OPRK1 | P41145 | 1/20 | 1.00 |
| ▸ | BLM | P54132 | 1/20 | 1.00 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 1.00 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.92 |
| ▸ | HPGD | P15428 | 2/20 | 0.79 |
| ▸ | NPC1 | O15118 | 1/20 | 0.76 |
| ▸ | MAPT | P10636 | 1/20 | 0.76 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Physostigmine SCHEMBL29482277 | 1.00 | ACHE (1.00) | ACHEBCHEKDM4EALDH1A1SMN1; SMN2 | |
| (+)-Physostigmine SCHEMBL15677750 | 1.00 | ACHE (1.00) | ACHEBCHEKDM4EALDH1A1SMN1; SMN2 | |
| Physostigmine SCHEMBL9988368 | 1.00 | ACHE (1.00) | ACHEBCHEKDM4EALDH1A1SMN1; SMN2 | |
| Physostigmine SCHEMBL4104619 | 1.00 | ACHE (1.00) | ACHEBCHEKDM4EALDH1A1SMN1; SMN2 | |
| Physostigmine SCHEMBL8800695 | 1.00 | ACHE (1.00) | ACHEBCHEKDM4EALDH1A1SMN1; SMN2 | |
| Physostigmine SCHEMBL24045 | 1.00 | ACHE (1.00) | ACHEBCHEKDM4EALDH1A1SMN1; SMN2 | |
| Physostigmine SCHEMBL13930339 | 1.00 | ACHE (1.00) | ACHEBCHEKDM4EALDH1A1SMN1; SMN2 | |
| Physostigmine SCHEMBL7581686 | 0.99 | ACHE (0.98) | ACHEBCHEKDM4EALDH1A1SMN1; SMN2 | |
| Physostigmine SCHEMBL7581684 | 0.99 | ACHE (0.98) | ACHEBCHEKDM4EALDH1A1SMN1; SMN2 | |
| Physostigmine SCHEMBL7587896 | 0.99 | ACHE (0.98) | ACHEBCHEKDM4EALDH1A1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 15909 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122080098-A | S-adenosyl homocysteine analogue, S-adenosyl-L-methionine analogue and application thereof | — | 2026-05-26 | — | — | CN | claimed |
| EP-4736841-A1 | A MUCOADHESIVE LAYER FOR BUCCAL ADMINISTRATION OF AN ACTIVE PHARMACEUTICAL INGREDIENT | IQ medical GmbH (DE) | 2026-05-06 | — | — | EP | claimed |
| EP-4724079-A2 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF AGE-RELATED MACULAR DEGENERATION | Stealth BioTherapeutics Inc. (US) | 2026-04-15 | — | — | EP | claimed |
| US-20260048096-A1 | METHODS AND COMPOSITIONS FOR PRESERVING THE RETINAL OUTER NUCLEAR LAYER (ONL), PHOTORECEPTORS, AND RETINAL THICKNESS | STEALTH BIOTHERAPEUTICS INC. (US) | 2026-02-19 | — | — | US | claimed |
| EP-4680228-A2 | OPHTHALMIC CREAM FORMULATIONS AND THEIR USES | Glaukos Corporation (US) | 2026-01-21 | — | — | EP | claimed |
| US-20250387372-A1 | OPHTHALMIC TOPICAL CREAM COMPOSITIONS AND METHODS | GLAUKOS CORP (US) | 2025-12-25 | — | — | US | claimed |
| EP-4659817-A2 | LIPOSOME COMPOSITION FOR USE IN PERITONEAL DIALYSIS | Versantis AG (CH) | 2025-12-10 | — | — | EP | claimed |
| EP-4635489-A1 | COMPOSITION FOR PREVENTING OR TREATING SIDE EFFECTS OF CHOLINESTERASE INHIBITORS | Dr.Noah Biotech Inc. (KR) | 2025-10-22 | — | — | EP | claimed |
| US-12414938-B2 | Ophthalmic topical cream compositions and methods | GLAUKOS CORPORATION (US) | 2025-09-16 | — | — | US | claimed |
| US-12390454-B2 | Use and composition for protection against organophosphorus poisoning | CLARENCE SMITH KATHLEEN E (US) | 2025-08-19 | — | — | US | claimed |
| US-4186184-A | Selective administration of drug with ocular therapeutic system | ALZA CORPORATION (US) | 1980-01-29 | — | — | US | claimed |
| US-4186185-A | Compositions comprising arylene substituted poly(orthoesters) containing useful agents | ALZA CORPORATION (US) | 1980-01-29 | — | — | US | claimed |
| US-4135514-A | Osmotic releasing system for administering ophthalmic drug to eye of animal | ALZA CORPORATION (US) | 1979-01-23 | — | — | US | claimed |
| US-4115544-A | DRUG PARTICLES MIXED WITH RELEASE RATE-CONTROLLING HOMOPOLYMER | ALZA CORPORATION (US) | 1978-09-19 | — | — | US | claimed |
| US-4066747-A | Polymeric orthoesters housing beneficial drug for controlled release therefrom | ALZA CORPORATION (US) | 1978-01-03 | — | — | US | claimed |
| US-4014335-A | Ocular drug delivery device | ALZA CORPORATION (US) | 1977-03-29 | — | — | US | claimed |
| US-4014334-A | Laminated osmotic system for dispensing beneficial agent | ALZA CORPORATION (US) | 1977-03-29 | — | — | US | claimed |
| US-4008719-A | Osmotic system having laminar arrangement for programming delivery of active agent | ALZA CORPORATION (US) | 1977-02-22 | — | — | US | claimed |
| US-4001388-A | POLYESTERS | ALZA CORPORATION (US) | 1977-01-04 | — | — | US | claimed |
| US-3962414-A | Structured bioerodible drug delivery device | ALZA CORPORATION (US) | 1976-06-08 | — | — | US | claimed |